RE:RE:RE:my guess"THe problem is a question of credability. Nothing, and I mean nothing that Gilles has ever publicly said would happen has ever happened in the timeline in that it was originally proposed."
Gilles original vision was to create a profitable base business that could support the development of the two active ingredients(beta glucan, avenanthramide) as biopharma products. He created a profitable base business that has grown at double digit rate for a decade. He moved CZO from a business incubator to its own state-of-the-art plant to get this done. Giant Symrise has complimented the long-standing product development partnership which has now been expanded to a preservative free beta glucan powder(PGX?). The cashflow from the base buisness has supported the development of the pipeline as envisioned as well as increased cash reserves. CZO has no debt and now sits before multiple key pipeline catalysts with the cash needed to get it done.
As for pipeline timelines this is a development stage science. Getting the timing right is a rare luxury with things that have never been developed in human history. There was also the COVID crisis and the biggest biotech market meltdown in history. The bigger issue with risky development science is does the science get done at all. Gilles originally set his ambitions on two things: the beta glucan pill, the avenanthramide pill. The avenanthramide pill was successfully developed and a trial is expected to begin enrollment in two months. To develop the beta glucan pill PGX had to be developed. That is a non-trivial task. The beta glucan pill was developed with PGX and a trial performed. Learnings were achieved. CZO can still pursue PGX-OBG as a powder drink given the results of the other company's trial. CZO has the best beta glucan with PGX and now Symrise is helping to develop a preservative free beta glucan powder.
Developing PGX-oat beta glucan pill led to the development of PGX-YBG, PGX-Alginate as well as PGX-YBG-Alginate. The CoQ10 bioavailability results have never been stronger with these new carriers. Blowout. PGX-YBG is also multi-fold more immune stimulatory than competitor YBG creating a potential gold standard. Dr. Kolb, a recognized authority in fibrosis says it may change the landscape it preclinical results are seen in humans. It is now approaching a clinical trial.
Avenanthramide and beta glucan has also been validated in established animal models for wound healing further strengthening these bioactives as medial products.
The truth is CZO has never been stronger. Gilles original vision continues to advance from the base business, to avenenanthramide, to beta glucan, and PGX and the new carriers. The original vision has only gotten bigger.
A transaction to NASDAQ along with the coming key catalysts will define the value.